Scilin®M30 — Competitive Intelligence Brief

Scilin®M30 (Scilin®M30) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Premixed insulin. Area: Diabetes.

marketed Premixed insulin Insulin receptor Diabetes Small molecule

Target snapshot

Scilin®M30 (Scilin®M30) — Chinese Diabetes Society. Scilin®M30 is a premixed insulin formulation that combines rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Scilin®M30 TARGET	Scilin®M30	Chinese Diabetes Society	marketed	Premixed insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Premixed insulin class)

1. Eli Lilly and Company · 2 drugs in this class
2. Adocia · 1 drug in this class
3. Chinese Diabetes Society · 1 drug in this class
4. The First Hospital of Jilin University · 1 drug in this class